Finished product reference
Dextrose
Injection, Solution · Intravenous · 5 % · 500 mL
- List code
- 5746
What it is and how it works
Mechanism of Action Dextrose Injection is used to supplement nutrition by providing glucose parenterally. Dextrose is oxidized to carbon dioxide and water, yielding energy.
Indications
Dextrose Injection is indicated as source of calories and fluid replenishment when mixed with amino acids or other compatible intravenous fluids for patients requiring parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient or contraindicated. Dextrose Injection is indicated as a source of calories when mixed with amino acids or other compatible intravenous fluids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient or contraindicated.
Dosage and administration (summary)
• Pharmacy Bulk Package. Not for direct intravenous infusion. • For slow intravenous infusion only into a: o Central vein, if final dextrose concentration is greater than 5% or osmolality is greater than 900 mOsm/L approximately. o Peripheral vein, if final dextrose concentration 5% or less and osmolality is less than 900 mOsm/L approximately. • Individualize dosage based on the patient’s clinical condition, body weight, nutritional/fluid requirements, as well as additional energy given orally/enterally. • Discontinue infusion of concentrated dextrose solutions slowly.
Contraindications
The use of Dextrose Injection is contraindicated in patients: • Who are severely dehydrated as hypertonic dextrose solution can worsen the patient’s hyperosmolar state . • Known hypersensitivity to dextrose . Severe dehydration.
Warnings and precautions
• Pulmonary Embolism due to Pulmonary Vascular Precipitates : If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. • Hyperglycemia or Hyperosmolar Hyperglycemic State : Monitor blood glucose and administer insulin as needed. • Hypersensitivity Reactions : Monitor for signs and symptoms and discontinue infusion if reactions occur. • Vein Damage and Thrombosis : Administer solutions containing more than 5% dextrose as the final concentration or solutions with an osmolarity of approximately 900 mOsm/L or greater through a central vein.
Pregnancy
Pregnancy Risk Summary Appropriate administration of Dextrose Injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations.
Storage and supply
Dextrose Injection 70%, USP (0.7 grams/mL) is available in a Pharmacy Bulk Package flexible plastic container for intravenous administration after appropriate dilution and is available in the following size in Table 2 below.
Source: Dextrose Monohydrate (Dextrose) — US FDA prescribing information, 2019-08-05, DailyMed. Summarised and shortened; the full label governs. Iranian registration, indications and labelling may differ.
Other presentations of the same active ingredient
- Injection, Solution · Intravenous · 3.33 %/0.3 % · 1000 mL395
- Injection, Solution · Intravenous · 3.33 %/0.3 % · 500 mL4907
- Injection, Solution · Intravenous · 5 %/0.45 % · 1000 mL51850
- Injection, Solution · Intravenous · 5 %/0.45 % · 500 mL2125
- Injection, Solution · Intravenous · 5 %/0.9 % · 1000 mL392
- Injection, Solution · Intravenous · 5 %/0.9 % · 250 mL2040
- Injection, Solution · Intravenous · 5 %/0.9 % · 500 mL393
- Injection, Solution · Intravenous · 10 % · 1000 mL410
- Injection, Solution · Intravenous · 10 % · 250 mL10083
- Injection, Solution · Intravenous · 10 % · 500 mL411
- Injection, Solution · Intravenous · 20 % · 50 mL15951
- Injection, Solution · Intravenous · 5 % · 1000 mL413
- Injection, Solution · Intravenous · 5 % · 250 mL6425
- Injection, Solution, Concentrate · Intravenous · 50 % · 200 mL52251
- Injection, Solution, Concentrate · Intravenous · 50 % · 400 mL52252
- Injection, Solution, Concentrate · Intravenous · 50 % · 50 mL15952
- Injection, Solution, Concentrate · Intravenous · 50 % · 500 mL52253
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.